Results 31 to 40 of about 604,720 (265)
Serving the scientific community: FEBS Open Bio in 2024
FEBS Open BioFEBS Open Bio is committed to not only publishing sound science but also to supporting early‐career researchers and the scientific community as a whole. In this editorial, we look back at how the journal recognised and rewarded excellent research in 2023
Duncan E. Wright, Miguel A. De la Rosa
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács +8 more
wiley +1 more source
An open chat with…Stuart Ferguson
FEBS Open Bio, 2021 Stuart Ferguson has been on the Editorial Board of FEBS Open Bio since its inception, and his expertise, dedication, and support have been invaluable for the journal’s growth and success.
Duncan Wright, Stuart J. Ferguson
doaj +1 more source
Visualization of Acoustic Comfort in an Open-Plan, High-Performance Glass Building
Buildings, 2022 The aesthetic and functional appeal of high-performance, open-plan office buildings presents special challenges. Extensive use of glass at the building’s perimeter to improve visual comfort and office communication can negatively impact acoustic comfort ...
Aldo A. Glean +2 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose Although not always achieved, complete chemotherapy‐induced nausea and vomiting (CINV) control is the conventional goal of CINV prophylaxis. In this two‐center, mixed‐methods study, we sought to understand the preferences of adolescent patients and family caregivers for CINV control endpoints.
Haley Newman +8 more
wiley +1 more source
Outcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With Sirolimus
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Live vaccination in patients with vascular anomalies (VA) receiving sirolimus remains controversial due to immunosuppressive effects and theoretical risks. Procedure This single‐center retrospective study included patients with VA less than 4 years old at the start of sirolimus therapy who were incompletely vaccinated.
Svatava Merkle +5 more
wiley +1 more source
Prevalence and Trajectory of Household Material Hardship Among Children With Advanced Cancer
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background/Objectives Families of children with advanced cancer living in poverty experience inferior outcomes including poor parent mental health and worse child quality of life. Household material hardship (HMH: food, housing, transportation, and/or utility insecurity) is a modifiable poverty exposure—and potential intervention target—that ...
Sarah Wright +13 more
wiley +1 more source
Jurnal Sisfokom, 2018 Dalam penerapannya Aplikasi office yang biasa di ajarkan khususnya di SMK biasanya menggunakan produk keluaran microsof yang merupakan apikasi berlisensi, sehingga sering ditemui penggunaan aplikasi office bajakan di komputer maupun laptop dari siswa ...
Surahmat Surahmat, Alfred Tenggono
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT End‐of‐life conversations with adolescents and young adults (AYAs) with cancer rarely occur without the guidance of healthcare professionals. As a part of the ‘Difficult Discussions’ study, focused on palliative care and advance care planning discussions with AYAs with cancer, we investigated the factors that healthcare professionals identify ...
Justine Lee +9 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Blinatumomab is a bispecific T‐cell engager approved for the treatment of pediatric B‐cell acute lymphoblastic leukemia (B‐ALL). Outpatient home infusion reduces hospitalization burden and optimizes resource utilization, but is logistically challenging.
Angela Parra del Riego +10 more
wiley +1 more source